$6250 | Single User
$12500 | Site License
$18750 | Enterprise License

Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027
[Report Updated: 14-02-2018]

Published by Delve Insight: 14 Feb 2018 | 201837 | In Stock
Related Topics: Renal Cell Carcinoma

Introduction

DelveInsight's "Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology and market outlook for the 7MM.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Metastatic Renal Cell Carcinoma (mRCC) Understanding and Treatment Algorithm

The market report provides the overview of the Metastatic Renal Cell Carcinoma (mRCC) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Metastatic Renal Cell Carcinoma (mRCC) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Metastatic Renal Cell Carcinoma (mRCC) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Metastatic Renal Cell Carcinoma (mRCC) Market Outlook

The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Metastatic Renal Cell Carcinoma (mRCC) market.

Metastatic Renal Cell Carcinoma (mRCC) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Metastatic Renal Cell Carcinoma (mRCC) Report Insights

• Patient Population in Metastatic Renal Cell Carcinoma (mRCC)

• Therapeutic Approaches in Metastatic Renal Cell Carcinoma (mRCC)

• Metastatic Renal Cell Carcinoma (mRCC) Pipeline Analysis

• Metastatic Renal Cell Carcinoma (mRCC) Market Size and Trends

• Metastatic Renal Cell Carcinoma (mRCC) Market Opportunities

• Impact of upcoming Therapies in Metastatic Renal Cell Carcinoma (mRCC)

Metastatic Renal Cell Carcinoma (mRCC) Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Metastatic Renal Cell Carcinoma (mRCC) Report Assessment

• Current Treatment Practices in Metastatic Renal Cell Carcinoma (mRCC)

• Unmet Needs in Metastatic Renal Cell Carcinoma (mRCC)

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• The report will help to develop Business Strategies by understanding the trends shaping and driving the Metastatic Renal Cell Carcinoma (mRCC) market

• Organize sales and marketing efforts by identifying the best opportunities for Metastatic Renal Cell Carcinoma (mRCC) market

• To understand the future market competition in the Metastatic Renal Cell Carcinoma (mRCC) market.

Table of Contents
for Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

  • 1. Report Introduction

    2. Metastatic Renal Cell Carcinoma (mRCC) Market Overview at a Glance

    2.1. Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2017

    2.2. Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2027

    3. Disease Background and Overview: Metastatic Renal Cell Carcinoma (mRCC)

    3.1. Introduction

    3.2. Symptoms

    3.3. Etiology

    3.4. Risk Factors

    3.5. Pathophysiology

    3.6. Diagnosis

    3.7. Treatment

    4. Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM

    4.3. Total Prevalent Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM – By Countries

    5. Epidemiology of Metastatic Renal Cell Carcinoma (mRCC) by Countries

    5.1. United States

    5.1.1. Assumptions and Rationale

    5.1.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.1.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.1.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.1.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.1.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.2. EU5

    5.3. Assumptions and Rationale

    5.4. Germany

    5.4.1. Assumptions and Rationale

    5.4.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.4.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.4.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.4.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.4.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.5. France

    5.5.1. Assumptions and Rationale

    5.5.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.5.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.5.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.5.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.5.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.6. Italy

    5.6.1. Assumptions and Rationale

    5.6.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.6.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.6.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.6.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.6.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.7. Spain

    5.7.1. Assumptions and Rationale

    5.7.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.7.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.7.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.7.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.7.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.8. United Kingdom

    5.8.1. Assumptions and Rationale

    5.8.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.8.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.8.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.8.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.8.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.9. Japan

    5.9.1. Assumptions and Rationale

    5.9.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.9.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.9.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.9.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.9.6. Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    6. Current Treatment & Medical practices

    6.1. Treatment Algorithm

    6.2. Treatment Guidelines

    7. Unmet Needs of the Metastatic Renal Cell Carcinoma (mRCC)

    8. Marketed Therapies

    8.1. Drug A: Company 1

    8.1.1. Drug Description

    8.1.2. Mechanism of Action

    8.1.3. Regulatory Milestones

    8.1.4. Advantages & Disadvantages

    8.1.5. Product Profile

    8.2. Drug B: Company 2

    8.2.1. Drug Description

    8.2.2. Mechanism of Action

    8.2.3. Regulatory Milestones

    8.2.4. Advantages & Disadvantages

    8.2.5. Product Profile

    9. Pipeline Therapies – At a glance

    10. Key Cross Competition

    11. Emerging Therapies for Metastatic Renal Cell Carcinoma (mRCC)

    11.1. Drug C: Company 3

    11.1.1. Drug Description

    11.1.2. Clinical Trials Details

    11.1.3. Safety and Efficacy Profile

    11.1.4. Advantages & Disadvantages

    11.1.5. Pipeline Development Activities

    11.1.6. Product Profile

    11.2. Drug D: Company 4

    11.2.1. Drug Description

    11.2.2. Clinical Trials Details

    11.2.3. Safety and Efficacy Profile

    11.2.4. Advantages & Disadvantages

    11.2.5. Pipeline Development Activities

    11.2.6. Product Profile

    12. Metastatic Renal Cell Carcinoma (mRCC) : 7MM Market Analysis

    12.1. 7MM Market Size of Metastatic Renal Cell Carcinoma (mRCC)

    12.2. 7MM Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC)

    12.3. 7MM Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products

    13. Metastatic Renal Cell Carcinoma (mRCC) : Country-Wise Market Analysis

    13.1. United States

    13.1.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in United States

    13.1.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in United States

    13.1.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in United States

    13.1.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2. EU-5

    13.2.1. Germany

    13.2.1.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Germany

    13.2.1.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Germany

    13.2.1.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Germany

    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.2. France

    13.2.2.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in France

    13.2.2.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in France

    13.2.2.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in France

    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.3. Italy

    13.2.3.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Italy

    13.2.3.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Italy

    13.2.3.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Italy

    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.4. Spain

    13.2.4.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Spain

    13.2.4.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Spain

    13.2.4.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Spain

    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.2.5. United Kingdom

    13.2.5.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom

    13.2.5.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in United Kingdom

    13.2.5.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in United Kingdom

    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

    13.3. Japan

    13.3.1. Market Size of Metastatic Renal Cell Carcinoma (mRCC) in Japan

    13.3.2. Percentage Share of drugs marketed for Metastatic Renal Cell Carcinoma (mRCC) in Japan

    13.3.3. Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Products in Japan

    13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

    14. Market Drivers

    15. Market Barriers

    16. Appendix

    17. Report Methodology

    17.1. Sources

    18. DelveInsight Capabilities

    19. Disclaimer

    20. About DelveInsight

    *Indication Specific

List Of Tables
in Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM

Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 7: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 8: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 9: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 10: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 11: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 12: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 13: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 14: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 15: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 16: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 17: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 18: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 19: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 20: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 21: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 22: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 27: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 28: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 29: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 30: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 31: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 32: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 33: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Table 34: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Table 35: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Table 36: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Table 37: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Table 42:7MM- Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 43:7MM- Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 44: United States-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Table 45: United States-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 46: United States-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 47: Germany-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Table 48: Germany-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 49: Germany-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 50: France-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Table 51: France-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 52: France-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 53: Italy-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Table 54: Italy-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 55: Italy-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 56: Spain-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Table 57: Spain-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 58: Spain-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 59:UK-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Table 60:UK-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 61:UK-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 62: Japan-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Table 63: Japan-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Table 64: Japan-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

List Of Figures, Charts and Diagrams
in Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Figure 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Figure 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Figure 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Figure 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Figure 7: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Figure 8: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Figure 9: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Figure 10: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Figure 11: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Figure 12: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Figure 13: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Figure 14: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Figure 15: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Figure 16: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Figure 17: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Figure 18: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Figure 19: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Figure 20: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Figure 21: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Figure 22: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Figure 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Figure 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Figure 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Figure 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Figure 27: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Figure 28: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Figure 29: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Figure 30: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Figure 31: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Figure 32: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Figure 33: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Figure 34: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Figure 35: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Figure 36: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Figure 37: Treatable Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Figure 42:7MM- Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 43:7MM- Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 44: United States-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Figure 45: United States-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 46: United States-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 47: Germany-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Figure 48: Germany-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 49: Germany-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 50: France-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Figure 51: France-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 52: France-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 53: Italy-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Figure 54: Italy-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 55: Italy-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 56: Spain-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Figure 57: Spain-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 58: Spain-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 59:UK-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Figure 60:UK-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 61:UK-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 62: Japan-Market Size of Metastatic Renal Cell Carcinoma (mRCC) in USD MM (2016-2027)

Figure 63: Japan-Market Share Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Figure 64: Japan-Market Sales of Metastatic Renal Cell Carcinoma (mRCC) by Therapies in USD MM (2016-2027)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

201837 | DIMI0138

Number of Pages

100

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Metastatic Renal Cell Carcinoma (mRCC) - Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)